HDL-C: Clinical equipoise and vascular endothelial function

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 3, 2013, Pages 343-353

  Campbell, Steven ^a   Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

atherosclerosis; cardiovascular disease; cholesterol; endothelial function; HDL; nitric oxide; vascular function

Indexed keywords

ANACETRAPIB; ATORVASTATIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; DALCETRAPIB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; G COUPLED S1PR1-5 RECEPTOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAROPIPRANT; LIPIDOME; MEMBRANE RECEPTOR; NICOTINIC ACID; NITRIC OXIDE; PROTEIN KINASE B; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCAVENGER RECEPTOR BI; TORCETRAPIB; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELLULAR PARAMETERS; CHOLESTEROL TRANSPORT; CHROMATOGRAPHY; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; GEL PERMEATION CHROMATOGRAPHY; HUMAN; IMMUNOAFFINITY CHROMATOGRAGHY; IN VITRO STUDY; LIPID METABOLISM; MACROPHAGE; MODULATION; NONHUMAN; OXIDATION; PARTICLE SIZE; PLEIOTROPY; PRECIPITATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRACENTRIFUGATION; VASCULAR ENDOTHELIAL FUNCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 84874900480     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.13.17     Document Type: Review

References (108)

1. Yusuf S, Hawken S, Ounpuu S et al. ; INTERHEART Study Investigators. Effect of potentially modifi able risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): CaseYcontrol study. Lancet 364 (9438) , 937-952 (2004).
2. Emerging Risk Factors Collaboration ; Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (18) , 1993-2000 (2009).
3. Genest JJ Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85 (6) , 2025-2033 (1992).
4. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-defi cient mouse. Proc. Natl Acad. Sci. USA 91 (20) , 9607-9611 (1994).
5. Van Eck M, Singaraja RR, Ye D et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26 (4) , 929-934 (2006).
6. Brunham LR, Singaraja RR, Duong M et al. Tissue-specifi c roles of ABCA1 infl uence susceptibility to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29 (4) , 548-554 (2009).
7. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B. Regression and stabilization of advanced murine atherosclerotic lesions: A comparison of LDL lowering and HDL raising gene transfer strategies. J. Mol. Med. 89 (6) , 555-567 (2011).
8. Clee SM, Zwinderman AH, Engert JC et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modifi ed risk for coronary artery disease. Circulation 103 (9) , 1198-1205 (2001).
9. Francis GA. The complexity of HDL. Biochim. Biophys. Acta 1801 (12) , 1286-1293 (2010).
10. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J. Lipid Res. 51 (8) , 2032-2057 (2010).
11. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380 (9841) , 572-580 (2012).
12. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: Proatherogenic HDL-An evolving fi eld. Nat. Clin. Pract. Endocrinol. Metab. 2 (9) , 504-511 (2006).
13. Barter P, Gotto AM, LaRosa JC et al. ; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357 (13) , 1301-1310 (2007).
14. Barter PJ, Caulfi eld M, Eriksson M et al. ; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357 (21) , 2109-2122 (2007).
15. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-Analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann. Intern. Med. 153 (12) , 800-808 (2010).
16. Ridker PM, Genest J, Boekholdt SM et al. ; JUPITER Trial Study Group. HDL cholesterol and residual risk of fi rst cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial. Lancet 376 (9738) , 333-339 (2010).
17. Rader DJ. Molecular regulation of HDL metabolism and function: Implications for novel therapies. J. Clin. Invest. 116 (12) , 3090-3100 (2006).
18. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50 (SUPPL.), S189-S194 (2009).
19. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54, 321-341 (2003).
20. Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-Associated lysosphingolipids. Trends Cardiovasc. Med. 15 (7) , 265-271 (2005).
21. Barter PJ. Cardioprotective effects of high-density lipoproteins: The evidence strengthens. Arterioscler. Thromb. Vasc. Biol. 25 (7) , 1305-1306 (2005).
22. Ogorzalek Loo RR, Yam L, Loo JA, Schumaker VN. Virtual two-dimensional gel electrophoresis of high-density lipoproteins. Electrophoresis 25 (14) , 2384-2391 (2004).
23. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5 (5) , 1431-1445 (2005).
24. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics 6 (2) , 721-730 (2006).
25. Hortin GL, Shen RF, Martin BM, Remaley AT. Diverse range of small peptides associated with high-density lipoprotein. Biochem. Biophys. Res. Commun. 340 (3) , 909-915 (2006).
26. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinfl ammatory properties of HDL. J. Clin. Invest. 117 (3) , 746-756 (2007).
27. Ståhlman M, Davidsson P, Kanmert I et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J. Lipid Res. 49 (2) , 481-490 (2008).
28. Green PS, Vaisar T, Pennathur S et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 118 (12) , 1259-1267 (2008).
29. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defi ned HDL subpopulations reveals particle-specifi c protein clusters: Relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29 (6) , 870-876 (2009).
30. Gordon S, Durairaj A, Lu JL, Davidson WS. High-density lipoprotein proteomics: Identifying new drug targets and biomarkers by understanding functionality. Curr. Cardiovasc. Risk Rep. 4 (1) , 1-8 (2010).
31. Alwaili K, Bailey D, Awan Z, Laboissiere S, Krimbou L, Genest J. HDL Proteomics in acute coronary syndromes. BBA: Mol. Cell Biol. Lipids (2011).
32. Quehenberger O, Armando AM, Brown AH et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51 (11) , 3299-3305 (2010).
33. Sorci-Thomas MG, Owen JS, Fulp B et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J. Lipid Res. 53 (9) , 1890-1909 (2012).
34. Nofer JR, van der Giet M, Tölle M et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113 (4) , 569-581 (2004).
35. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 150 (4) , 470-479 (2007).
36. von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr. Opin. Lipidol. 20 (3) , 197-205 (2009).
37. Argraves KM, Gazzolo PJ, Groh EM et al. High density lipoprotein- Associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 283 (36) , 25074-25081 (2008).
38. Argraves KM, Sethi AA, Gazzolo PJ et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 10, 70 (2011).
39. Liu X, Xiong SL, Yi GH. ABCA1, ABCG1, and SR-BI: Transit of HDL-Associated sphingosine-1-phosphate. Clin. Chim. Acta 413 (3-4) , 384-390 (2012).
40. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in athero-sclerosis. J. Lipid Res. 50 (SUPPL.) , S207-S212 (2009).
41. Dernick G, Obermüller S, Mangold C et al. Multidimensional profi ling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays. J. Lipid Res. 52 (12) , 2323-2331 (2011).
42. Rosenson RS, Brewer HB Jr, Chapman MJ et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57 (3) , 392-410 (2011).
43. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60 (6) , 508-516 (2012).
44. Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains effi cient pre-β-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51 (12) , 3443-3454 (2010).
45. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96 (12) , 1221-1232 (2005).
46. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6 (7) , 455-463 (2009).
47. Iatan I, Bailey D, Ruel I et al. Membrane microdomains modulate oligomeric ABCA1 function: Impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis. J. Lipid Res. 52 (11) , 2043-2055 (2011).
48. Bailey D, Ruel I, Hafi ane A et al. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: Implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res. 51 (4) , 785-797 (2010).
49. Baigent C, Keech A, Kearney PM et al. ; Cholesterol Treatment Trialists' (CTT) Collaborators. Effi cacy and safety of cholesterol-lowering treatment: Prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (9493) , 1267-1278 (2005).
50. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-Analysis. Clin. Ther. 31 (2) , 236-244 (2009).
51. Genest J, Libby P. Lipoprotein Disorders and CAD. In: Braunwald's Heart Disease. Braunwald E, Libby P, Zipes D, Bonow R (Eds). Saunders, New York, NY, USA (2011).
52. Grundy SM, Cleeman JI, Daniels SR et al. ; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation 112 (17) , 2735-2752 (2005).
53. Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult Y2009 recommendations. Can. J. Cardiol. 25 (10) , 567-579 (2009).
54. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis? J. Lipid Res. 51 (8) , 2058-2073 (2010).
55. Awan Z, Al Waili K, Alrasadi K, Genest J. Treatment of low high density lipoprotein cholesterol. Can J. Cardiol. 24, 27-31 (2008).
56. Alrasadi K, Awan Z, Alwaili K et al. Comparison of treatment of severe high-density lipoprotein cholesterol defi ciency in men with daily atorvastatin (20 mg) versus fenofi brate (200 mg) versus extended-release niacin (2 g). Am. J. Cardiol. 102 (10) , 1341-1347 (2008).
57. Greenland P, Alpert JS, Beller GA et al. ; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122 (25) , e584-e636 (2010).
58. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-Analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17 (6) , 631-636 (2006).
59. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA 298 (7) , 786-798 (2007).
60. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290 (17) , 2292-2300 (2003).
61. Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 338, b92 (2009).
62. Carlson LA. Nicotinic acid: The broadspectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258 (2) , 94-114 (2005).
63. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361 (22) , 2113-2122 (2009).
64. Boden WE, Probstfi eld JL, Anderson T et al. ; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365 (24) , 2255-2267 (2011).
65. Abourbih S, Filion KB, Joseph L et al. Effect of fi brates on lipid profi les and cardiovascular outcomes: A systematic review. Am. J. Med. 122 (10) , 962. e1-962.e8 (2009).
66. Jun M, Foote C, Lv J et al. Effects of fi brates on cardiovascular outcomes: A systematic review and meta-Analysis. Lancet 375 (9729) , 1875-1884 (2010).
67. Ginsberg HN, Elam MB, Lovato LC.; ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. NEJM 362, 1563 (2010).
68. Stein EA, Stroes ES, Steiner G et al. Safety and tolerability of dalcetrapib. Am. J. Cardiol. 104 (1) , 82-91 (2009).
69. Stroes ES, Kastelein JJ, Bénardeau A et al. Dalcetrapib: No off-target toxicity on blood pressure or on genes related to the reninYangiotensinYaldosterone system in rats. Br. J. Pharmacol. 158 (7) , 1763-1770 (2009).
70. Fayad ZA, Mani V, Woodward M et al. ; dal-PLAQUE Investigators. Safety and effi cacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet 378 (9802) , 1547-1559 (2011).
71. Lüscher TF, Taddei S, Kaski JC et al. ; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur. Heart J. 33 (7) , 857-865 (2012).
72. Schwartz GG, Olsson AG, Abt M et al. ; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367 (22) , 2089-2099 (2012).
73. Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled Phase I studies. Lancet 370 (9603) , 1907-1914 (2007).
74. Bloomfi eld D, Carlson GL, Sapre A et al. Effi cacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157 (2) , 352-360.e2 (2009).
75. Cannon CP, Shah S, Dansky HM et al. ; Determining the Effi cacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363 (25) , 2406-2415 (2010).
76. Nicholls SJ, Brewer HB, Kastelein JJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA 306 (19) , 2099-2109 (2011).
77. Degoma EM, Rader DJ. Novel HDLdirected pharmacotherapeutic strategies. Nat. Rev. Cardiol. 8 (5) , 266-277 (2011).
78. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7 (2) , 143-155 (2008).
79. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol effl ux capacity, highdensity lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364 (2) , 127-135 (2011).
80. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as infl uenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51 (23) , 2199-2211 (2008).
81. Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121 (1) , 110-122 (2010).
82. Rye KA, Barter PJ. Anti-infl ammatory actions of HDL: A new insight. Arterioscler. Thromb. Vasc. Biol. 28 (11) , 1890-1891 (2008).
83. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-Atherogenic properties of HDL. J. Lipid Res. 50 (SUPPL.) , S195-S200 (2009).
84. Tang C, Oram JF. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim. Biophys. Acta 1791 (7) , 563-572 (2009).
85. Besler C, Heinrich K, Rohrer L et al. Mechanisms underlying adverse effects of HDL on eNOS-Activating pathways in patients with coronary artery disease. J. Clin. Invest. 121 (7) , 2693-2708 (2011).
86. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278 (11) , 9142-9149 (2003).
87. Nicholls SJ, Dusting GJ, Cutri B et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinfl ammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (12) , 1543-1550 (2005).
88. Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains effi cient pre-β-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51 (12) , 3443-3454 (2010).
89. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoproteininduced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275 (15) , 11278-11283 (2000).
90. Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7 (7) , 853-857 (2001)
91. Saddar S, Mineo C, Shaul PW. Signaling by the high-Affi nity HDL receptor scavenger receptor B type I. Arterioscler. Thromb. Vasc. Biol. 30 (2) , 144-150 (2010).
92. Spieker LE, Sudano I, Hürlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (12) , 1399-1402 (2002).
93. Bisoendial RJ, Hovingh GK, Levels JH et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (23) , 2944-2948 (2003).
94. Rämet ME, Rämet M, Lu Q et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 41 (12) , 2288-2297 (2003).
95. Terasaka N, Westerterp M, Koetsveld J et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler. Thromb. Vasc. Biol. 30 (11) , 2219-2225 (2010).
96. Sugano M, Tsuchida K, Makino N.
97. High-density lipoproteins protect endothelial cells from tumor necrosis factor-α-induced apoptosis. Biochem. Biophys. Res. Commun. 272 (3) , 872-876 (2000).
98. Seetharam D, Mineo C, Gormley AK et al. High-density lipoprotein promotes endothelial cell migration and re-endothelialization via scavenger receptor-B type I. Circ. Res. 98 (1) , 63-72 (2006).
99. Feng Y, Jacobs F, Van Craeyveld E et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 28 (2) , 278-283 (2008).
100. Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, von Eckardstein A. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. C irc. Res. 104 (10) , 1142-1150 (2009).
101. Sumi M, Sata M, Miura S et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27 (4) , 813-818 (2007).
102. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 26 (5) , 1144-1149 (2006).
103. Van Linthout S, Spillmann F, Lorenz M et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 53 (4) , 682-687 (2009).
104. Kimura T, Sato K, Malchinkhuu E et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23 (7) , 1283-1288 (2003).
105. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89 (1), E1-E7 (2001).
106. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353 (10) , 999-1007 (2005).
107. Werner N, Wassmann S, Ahlers P et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res. Cardiol. 102 (6) , 565-571 (2007).
108. Padfi eld GJ, Newby DE, Mills N.L. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J. Am. Coll. Cardiol. 55 (15) , 1553-1565 (2010).